CAMBRIDGE, Mass., June 13 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) today announced it has licensed from Genentech,
Inc. (NYSE: DNA) worldwide, patent rights relating to fusion proteins,
described as immunoadhesons. The non-exclusive licenses will apply to
AMEVIVE(R) (alefacept), currently approved in the United States for moderate-
to-severe chronic plaque psoriasis, and other potential products in Biogen's
product pipeline.
(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Biogen will pay an undisclosed royalty to Genentech beginning immediately.
This has already been incorporated in Biogen's financial guidance for 2003.
About Biogen
Biogen is the world's oldest independent biotechnology company and a
leader in biologics research, development and manufacturing. A pioneer in
leading edge research in immunology, neurobiology and oncology, Biogen brings
novel therapies to improve patients' lives around the world through its global
marketing capabilities. For press releases and additional information about
the company, please visit http://www.biogen.com.
Media Contact:
Amy McKnight
Associate Director, Public Affairs
Biogen, Inc.
Tel: (617) 914-6524
Investment Community Contact:
Christina Dillon
Manager, Investor Relations
Biogen, Inc.
Tel: (617) 679-2812
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Amy McKnight, Associate Director, Public
Affairs, +1-617-914- 6524; or Christina Dillon, Manager, Investor
Relations, +1-617-679-2812, both for Biogen, Inc. /First Call
Analyst:
|
